Critical Assessments of Computational Hit-finding Experiments Challenge #4: Targeting the Tyrosine Kinase Binding Domain of the E3 Ligase Casitas B-Lineage Lymphoma Proto-Oncogene B, an Immuno-Oncology Target
Year: 2026
Type: article
Abstract: The critical assessments of computational hit-finding experiments (CACHE) are prospective benchmarking exercises where small molecule ligands predicted for a nominated protein of interest are procured and tested experimentally. In CACHE #4, 23 participating teams each selected up to 100 compounds designed to bind the E3 ligase CBLB, an immuno-oncology target. The organizers released the first public structure of CBLB in complex with a known ligand at the outset of the challenge to enable the discovery of chemically novel molecules. Out of the 1688 compounds collectively predicted, ten compounds from nine participants showed some sign of activity (primary hits), but only two were convincingly confirmed (validated hits) across multiple biophysical binding assays and in subsequent analogs, and only one of them was chemically novel. The apparent difficulty of finding novel CBLB ligands, previously reflected by the chemical similarity of inhibitors from the patent literature, suggests that potent CBLB hit molecules were either rare in the screened commercial libraries, or that computational methods may have struggled to retrieve presumably present but weak ligands, or that the conformational dynamics of the binding site was not sufficiently accounted for. The successful method was strikingly atypical. Selection from a chemical binding similarity classifier followed by a random forest binding affinity predictor trained on inhibitors from the patent literature was refined using a diffusion-model binding pose predictor. The road to an ML-driven breakthrough in computational hit-finding can take unexpected turns. Which of these turns reveal novel horizons and which are mere distractions will best be investigated and answered collectively. The discovery in CACHE #4 of a novel series of CBLB ligands is not a trivial achievement and may inform medicinal chemistry efforts toward clinical candidates that complement immune checkpoint inhibition to elicit antitumor immune response in cancer patients.
Authors: Madhushika Silva, Oleksandra Herasymenko, Abd Al-Aziz A. Abu-Saleh, Suzanne Ackloo, Rima Al-awar, Cheryl H. Arrowsmith, Ryota Ashizawa, David J. Bearss, Hartmut, Beck, Kevin P. Bishop, Vincent Blay, Hugo J. Bohórquez, Albina Bolotokova, Duanhua Cao, Irene Chau, Lin Chen, Sandro Cosconati, Wim Dehaen, Kristina Edfeldt, Elisa Gibson, Gediminas Gumbis, Christoph Gorgulla, Anders Gunnarsson, Rachel J. Harding, Laurent Hoffer, Anders Hogner, Douglas R. Houston, Oleksii Hrabovskyi, John J. Irwin, Diane Joseph- McCarthy, Andrea Karlova, Sergei Kotelnikov, Dima Kozakov, Uta Lessel, Peter Loppnau, Wei Lu, Kyle Medley, Miles McGibbon, Yurii Moroz, Charuvaka Muvva, Benito Natale, Boyang Ni, Eva Nittinger, Tudor I. Oprea, Brooks Paige, Keunwan Park, Gennady Poda, Konstantin Popov, Mykola V. Protopopov, Vera Pütter, Edina Rosta, Michele Roggia, Yogesh Sabnis, Christopher Secker, Olha Semenenko, Conrad V. Simoben, Olga O. Tarkhanova, Dakota Treleaven, Alexander Tropsha, David Uehling, Hariprasad Vankayalapati, Jude Wells, James Wellnitz, Yvonne Westermaier, Lars Wortmann, Jie Yu, Jixian Zhang, Runze Zhang, Mingyue Zheng, Shuangjia Zheng, Yuchen Zhou, Sara Ziadat, Levon Halabelian, Matthieu Schapira
Institutions: Structural Genomics Consortium, Ontario Institute for Cancer Research, University of Toronto, University Health Network, Princess Margaret Cancer Centre, The University of Texas at Austin, Bayer (Germany), University of California, Santa Cruz, Chinese Academy of Sciences, University of Edinburgh, University of Campania "Luigi Vanvitelli", University of Chemistry and Technology, Prague, Karolinska University Hospital, Karolinska Institutet, St. Jude Children's Research Hospital, Palladin Institute of Biochemistry, University of California, San Francisco, Boston University, University College London, Massachusetts Institute of Technology, Boehringer Ingelheim (Germany), BioNTech (United States), Taras Shevchenko National University of Kyiv, Enamine (Ukraine), Korean Association Of Science and Technology Studies, Korea Institute of Science and Technology, AstraZeneca (United Kingdom), University of North Carolina at Chapel Hill, Zuse Institute Berlin, Boehringer Ingelheim (Austria), Harvard University
Language: English
Subfield: Drug Discovery
Domain: Life Sciences
Open Access status: green
Funders: Bill and Melinda Gates Foundation, Amgen, Bristol-Myers Squibb, McGill University, Diamond Light Source, European Federation of Pharmaceutical Industries and Associations, Innovative Health Initiative, European Commission, Deutsche Forschungsgemeinschaft, Ministry of Oceans and Fisheries, Korea Institute of Science and Technology, National Research Foundation of Korea, Hospital for Sick Children, Innovative Medicines Initiative, Korea Institute of Marine Science and Technology promotion, Ministry of Science and ICT, South Korea, Alliance de recherche numérique du Canada, HORIZON EUROPE Framework Programme, Canadian Institutes of Health Research, Compute Ontario
OpenAlex ID: W7167712795
